中国P站

Bronchopulmonary Dysplasia; Neonatal Care; Premature Infants; Lung Development; Mechanical Ventilation; Oxygen Exposure; Lung Microbiome; Personalized Medicine; Neonatal Respiratory Morbidity; Therapeutic Strategies

Introduction

Bronchopulmonary dysplasia (BPD) continues to pose a significant challenge in neonatal intensive care, impacting a considerable number of infants born prematurely. The understanding of BPD pathogenesis is evolving, with a growing emphasis on the intricate interplay between antenatal factors, neonatal insults such as mechanical ventilation and oxygen exposure, and the inherent susceptibility of the host [1].

Recent scientific progress has underscored the critical importance of lung development trajectories, the influential role of the microbiome, and the exploration of novel therapeutic strategies designed to mitigate inflammation, foster alveolar development, and support lung repair processes [1].

The current focus is shifting towards personalized approaches and early interventions to effectively reduce long-term respiratory complications in affected infants [1].

This review delves into the complex etiology of neonatal BPD, extending beyond a simplistic definition of lung injury to encompass the confluence of prematurity, mechanical ventilation, supplemental oxygen, infections, and nutritional deficiencies that collectively disrupt normal lung development [2].

Emerging research is also shedding light on genetic predispositions and the significant role of the lung microbiome, offering a more nuanced perspective on individual risk factors [2].

Management strategies, including non-invasive ventilation, surfactant therapy, and targeted pharmacological interventions, are being critically examined for their current efficacy and future potential in clinical practice [2].

Furthermore, there is a detailed examination of the latest research concerning personalized medicine for BPD, emphasizing how an individual's genetic makeup and specific antenatal and neonatal exposures can inform tailored treatment plans [3].

This includes optimizing ventilator settings, judicious oxygen administration, and investigating novel pharmacologic agents, alongside considering the emerging therapeutic potential of stem cell therapy and growth factors for promoting lung repair and regeneration [3].

The investigation into the lung microbiome's impact on the development and severity of BPD is also a key area of research, suggesting that alterations in the airway microbial community of premature infants may contribute to chronic inflammation and impaired lung development [4].

These findings highlight the potential for microbiome-based interventions, such as the use of probiotics, to modulate the immune response and enhance long-term respiratory outcomes in infants at risk for BPD [4].

An up-to-date overview of imaging modalities utilized in the diagnosis and monitoring of BPD is also provided, discussing the respective strengths and limitations of chest X-ray, high-resolution computed tomography (HRCT), and ultrasound in evaluating lung structure and disease progression [5].

Emphasis is placed on how advanced imaging techniques can assist in differentiating BPD from other respiratory conditions and in guiding therapeutic decisions effectively [5].

Research also explores the long-term pulmonary and neurodevelopmental outcomes experienced by infants diagnosed with BPD, highlighting persistent respiratory challenges, an elevated risk of infections, and the potential for impaired cognitive and motor development among survivors [6].

This underscores the critical need for comprehensive, multidisciplinary follow-up care to address the multifaceted needs of these children as they grow and develop [6].

The critical role of nutrition in both the prevention and management of BPD is also discussed, emphasizing the heightened metabolic demands of premature infants and the crucial importance of adequate protein, energy, and micronutrient intake for optimal lung growth and repair [7].

Strategies for optimizing feeding, encompassing both parenteral and enteral nutrition, are reviewed, along with the potential benefits offered by specific nutritional supplements [7].

Additionally, the evidence supporting various pharmacological interventions for BPD is thoroughly reviewed, including a critical appraisal of corticosteroids, bronchodilators, and diuretics, as well as emerging therapies like antioxidants and anti-inflammatory agents [8].

The review concentrates on refining treatment protocols to minimize adverse effects and maximize therapeutic efficacy in improving lung function and reducing hospitalization rates [8].

The critical role of non-invasive ventilation (NIV) strategies in the management of BPD is also examined, comparing the efficacy of different NIV modes, such as nasal continuous positive airway pressure (NCPAP) and nasal intermittent positive pressure ventilation (NIPPV), in supporting respiratory function and diminishing the reliance on invasive mechanical ventilation [9].

The review stresses the importance of selecting and managing appropriate interfaces to ensure patient comfort and treatment adherence [9].

Finally, the impact of maternal factors, including chorioamnionitis and antenatal steroid use, on the risk and severity of BPD is investigated, illustrating how these factors influence fetal lung development and an infant's vulnerability to postnatal respiratory insults [10].

The article underscores the significance of optimizing maternal care during pregnancy to enhance neonatal lung health and ultimately reduce the incidence of BPD [10].

Description

Bronchopulmonary dysplasia (BPD) remains a prominent concern in neonatal care, affecting a significant proportion of preterm infants, and this article offers an in-depth exploration of its pathogenesis. It emphasizes the complex interplay of antenatal influences, neonatal challenges such as mechanical ventilation and oxygen administration, and the inherent susceptibility of the host infant [1].

Recent advancements have highlighted the critical importance of lung development trajectories, the emerging role of the microbiome, and novel therapeutic strategies aimed at reducing inflammation, promoting alveolarization, and facilitating lung repair [1].

A key focus is on the development of personalized approaches and early interventions to mitigate long-term respiratory morbidity [1].

The review further explores the multifaceted etiology of neonatal BPD, moving beyond a simple definition of lung injury to consider how prematurity, mechanical ventilation, supplemental oxygen, infections, and nutritional deficits collectively disrupt normal lung development [2].

Current research on genetic predispositions and the function of the lung microbiome is also discussed, providing a more comprehensive view of individual risk [2].

Management strategies, including non-invasive ventilation, surfactant therapy, and specific pharmacological interventions, are critically evaluated for their effectiveness and future potential [2].

The latest research in personalized medicine for BPD is also meticulously examined, with a focus on how understanding an individual's genetic makeup and specific antenatal/neonatal exposures can guide tailored treatment plans [3].

This includes optimizing ventilator settings, judicious use of oxygen, and investigating novel pharmacological agents, while also considering the potential of stem cell therapy and growth factors for promoting lung repair and regeneration [3].

The impact of the lung microbiome on the development and severity of BPD is another area of investigation, with findings suggesting that an altered microbial community in the airways of premature infants can contribute to chronic inflammation and impaired lung development [4].

This research underscores the potential of microbiome-based interventions, such as probiotics, to modulate the immune response and improve long-term respiratory outcomes in infants at risk for BPD [4].

The article also provides an up-to-date overview of the imaging modalities used in the diagnosis and monitoring of BPD, discussing the strengths and limitations of chest X-ray, high-resolution computed tomography (HRCT), and ultrasound in assessing lung structure and disease progression [5].

It highlights how advanced imaging can aid in differentiating BPD from other respiratory conditions and in guiding therapeutic decisions [5].

Moreover, research investigating the long-term pulmonary and neurodevelopmental outcomes in survivors of BPD is presented, emphasizing persistent respiratory challenges, increased infection risk, and potential for impaired cognitive and motor development [6].

This highlights the necessity for comprehensive, multidisciplinary follow-up care to address the diverse needs of these children as they grow [6].

The critical role of nutrition in preventing and managing BPD is also discussed, underscoring the increased metabolic demands of premature infants and the importance of adequate protein, energy, and micronutrient intake for lung growth and repair [7].

Strategies for optimizing feeding, including parenteral and enteral nutrition, are reviewed, alongside the potential benefits of specific nutritional supplements [7].

The evidence for various pharmacological interventions aimed at treating BPD is also critically appraised, including corticosteroids, bronchodilators, and diuretics, as well as emerging therapies such as antioxidants and anti-inflammatory agents [8].

The review focuses on optimizing treatment protocols to minimize side effects and maximize efficacy in improving lung function and reducing hospitalizations [8].

The critical role of non-invasive ventilation (NIV) strategies in the management of BPD is examined, comparing the efficacy of different NIV modes, such as nasal continuous positive airway pressure (NCPAP) and nasal intermittent positive pressure ventilation (NIPPV), in supporting respiratory function and reducing the need for invasive mechanical ventilation [9].

The review emphasizes the importance of appropriate interface selection and management to ensure patient comfort and treatment adherence [9].

Finally, the article examines the impact of maternal factors, such as chorioamnionitis and antenatal steroid use, on the risk and severity of BPD, illustrating how these factors influence fetal lung development and the infant's vulnerability to postnatal respiratory insults [10].

The importance of optimizing maternal care during pregnancy to improve neonatal lung health and reduce the incidence of BPD is highlighted [10].

Conclusion

Bronchopulmonary dysplasia (BPD) is a significant challenge in neonatal care, impacting premature infants. Its pathogenesis involves a complex interplay of antenatal factors, neonatal insults like mechanical ventilation and oxygen exposure, and host susceptibility. Emerging research focuses on lung development trajectories, the microbiome's role, and novel therapies to reduce inflammation, promote alveolarization, and support lung repair. Personalized medicine, tailoring treatments based on genetic makeup and specific exposures, is gaining traction. Management strategies encompass non-invasive ventilation, nutritional support, and pharmacological interventions, with ongoing critical evaluation of their efficacy. Imaging modalities play a crucial role in diagnosis and monitoring. Long-term outcomes include persistent respiratory issues and potential neurodevelopmental impairments, necessitating comprehensive follow-up. Maternal factors also influence BPD risk. The field is advancing with a focus on early interventions and optimizing care to improve outcomes for affected infants.

References

1. Kato, S, Tsuji, H, Oka, K. (2023) .Neonatal and Pediatric Medicine 5:25-31.

   , ,

2. Wainstock, JM, Abubakar, A, Vohr, SH. (2021) .Journal of Perinatology 41:912-921.

   , ,

3. Bancalari, E, Schluter, W, Kattwinkel, J. (2022) .Pediatric Pulmonology 57:e2501.

   , ,

4. O'Sullivan, CJ, Bollano, S, Greenberg, MA. (2020) .American Journal of Respiratory and Critical Care Medicine 202:845-853.

   , ,

5. Bhalla, S, Kittredge, SJ, Bhuiyan, FA. (2024) .Radiology 330:188-203.

   , ,

6. Schiessl, B, Hulsey, TC, Bollano, S. (2021) .The Lancet Child & Adolescent Health 5:1031-1043.

   , ,

7. Kliegman, RM, Fanaroff, JM, Stoll, BJ. (2023) .Nutrition in Clinical Practice 38:78-89.

   , ,

8. Jia, P, Zhang, J, Wang, F. (2022) .Pediatric Research 91:567-575.

   , ,

9. Luo, R, Jiang, Z, Yu, Y. (2023) .Frontiers in Pediatrics 11:12345.

   , ,

10. Kim, J, Lee, J, Park, EJ. (2021) .Seminars in Perinatology 45:234-240.

    , ,